Estimates not changed in an entire week...Banro continue to discount these results..... -0.03 - 0.03
-0.12 for the entire 2015... Who is?.. and where is??
Sentiment: Strong Buy
...Be positive...Some analyst has to come out with very positive numbers about Banro turnaround...Maybe they are accumulating shares...
TBIO has Goldman Sachs with an active position of shareholder...Not Trov and Bioc at least for now within liquid biopsy stocks....
12 millions shares outstanding..
2015 ASCO Annual Meeting
J Clin Oncol 33:5s, 2015 (suppl; abstr e12554)
Author(s): Katherine Anne Richardson, Stephanie Peterson, Jen Bevilacqua, Stephanie Veys, Vicki Rosendale, Benjamin L. Legendre, Keith Christopher Bible, Honey Reddi; Transgenomic, Inc., Omaha, NE; Transgenomic, Inc., New Haven, CT; Mayo Clinic, Rochester, MN
Background: RAS family genes affect signal transduction downstream of EGFR and play a critical role in determining response to EGFR-targeted therapies. Primary resistance to EGFR-specific Tyrosine Kinase Inhibitors (including cetuximab and panitumumab) in colon cancer is often due to the presence of RAS mutations. KRAS and NRAS mutations are found in ~25% of human tumors and lead to constitutive activation of Ras proteins. About 35-45% of colorectal tumors carry KRAS Exon 2 (codon 12 and 13) mutations which constitutively activate signaling downstream of EGFR. Presence of KRAS Exon 2 mutation status therefore predicts response to anti-EGFR therapy. However, ~10% of patient tumors that do not have a mutation in KRAS exon 2, have been found recently to harbor mutations in KRAS exons 3 or 4 or in NRAS exons 2, 3, or 4. Methods: The Transgenomic CRC RAScan test was developed to offer expanded screening of the KRAS and NRAS genes across exons 2, 3 and 4 respectively to better guide management decision making in metastatic CRC. Results: Using this approach, evaluation of 128 CRC cases tested in our facility in 2014 identified 29 cases (23%) with relevant mutations. Of these, 13 cases harbored a mutation in the canonical KRAS exon 2 at codons 12/13 (45%). The remaining 16 cases (55%) had mutations in KRAS exon 3 (1/16), KRAS exon 4 (7/16), NRAS exon 2 (5/16) and NRAS exon 3 (3/16). Evidence demonstrates that individuals with mutations in KRAS exon 3 and 4 as well as in NRAS exons 2, 3 and 4 also respond poorly to anti-EGFR treatments2, suggesting that screening for mutation
Net loss for the first quarter of 2015 was $3.8 million, or $0.37 per share based on 10.4 million weighted average shares outstanding. This compared with a net loss of $5.1 million, or $1.96 per share based on 2.6 million weighted average shares outstanding, for the first quarter of 2014. The lower net loss was primarily due to a decrease of $1.6 million in non-cash interest expense and change in fair value of warrant liability, as well as a $0.6 million decrease in stock-based compensation expense, both related to the Company's initial public offering in February 2014, partially offset by increases associated with the deployment of the sales and marketing organization since the first quarter of 2014.
According to the trading action nobody seems to want tbio shares... On the contrary the first and the second institutional updates are positive...Third security hold big position and Potomac increase...
THIRD SECURITY, LLC 03/31/2015 770,490 0 0.00 1,140
POTOMAC CAPITAL MANAGEMENT, INC. 03/31/2015 423,907 140,000 49.31 627
..12,161,156 issued and outstanding shares...Randal Kirk over 4 millions shares..Orin Hirschman, Kevin Douglas,Dolphin Offshore Partners, L.P. over 1 miilion each...From the last SEC filing...
This is the correct number of Fidelity mutual fund ...
The 5 millions positions you mentioned yesterday, were before the 2013 reverse split..
Fidelity® Select Biotechnology Portfolio
...Some liquid biopsy stock will be for sure the buy of a lifetime...TBIO is completely undiscovered as liquid biopsy stock...Maybe some other news will change this situation...A FDA update announced in the CC for the next few days... TBIO is ice cold at the present time...
CAMBRIDGE, UK, and OMAHA, NE, USA (April, 23, 2015) --Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through advanced diagnostic tests and clinical and research services, today announced a new Original Equipment Manufacture (OEM) agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s Diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCRTM (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed.
Sentiment: Strong Buy